Imiquimod (topical use)

DRUG3 trials

Sponsors

Moberg Pharma AB, University of Southern California

Conditions

Actinic KeratosisHealthyLeukoplakiaLeukoplakia OralOral Dysplasia

Phase 1

A Double-blind, Randomized, Single Centre, Vehicle-controlled Study to Evaluate the Safety and Tolerability of a New Topical Formulation Containing 0,09% Imiquimod (Limtop) in Healthy Subjects

CompletedNCT01567683

Moberg Pharma ABHealthy

Updated: 2012-05-28

Topical Imiquimod Treatment of Oral Dysplasia

RecruitingNCT07210775

University of Southern CaliforniaLeukoplakia, Leukoplakia Oral, Oral Dysplasia

Start: 2025-10-01End: 2027-10-01Target: 20Updated: 2026-03-04

Phase 2

Efficacy and Safety of a New Topical Formulation With Imiquimod (Limtop) Applied 1, 3 or 7 Times Weekly During 2 x 2 Weeks Treatment for Actinic Keratosis on the Head

CompletedNCT01611480

Moberg Pharma ABActinic Keratosis

Updated: 2013-06-26